AD-SMART Clinical Trial will Study Diabetes and ADHD drugs on Alzheimer’s patients

The recently initiated AD-SMART clinical trial in the UK is testing Diabetes and ADHD drugs on Alzheimer’s patients to examine if the medicines are working on the symptoms.

News Source: https://www.bbc.com/

The way we see Alzheimer's disease therapies could be drastically changed by a unique clinical trial that was started in the UK. The AD-SMART trial, which tests several medications at once, gives Alzheimer's research new hope. Scientists are repurposing current drugs, including those for type-2 diabetes and ADHD, to explore if they help protect the brain rather than waiting ten years for answers.

Conventional trials proceed at a difficult "one drug, one trial" pace. By employing a multi-arm, multi-stage platform, a strategy that has proven extremely effective in cancer research the AD-SMART trial expedites this. A medication is swiftly discontinued and replaced with another if it isn't working.

The experiment provides a crucial transition from passive waiting to active battling for families dealing with a diagnosis. The first patient to begin treatment is Angela Bucksey, a 67-year-old Cambridgeshire resident with a strong family history of Alzheimer's. Angela views the trial as a means of regaining control, stating “We have Alzheimer's in the family, my mother had it and my aunts, so it was a disappointment rather than a shock when I was diagnosed because I knew it would restrict my life. But I was determined that it wasn't going to define me. At least you are doing something. Instead of just sitting there, you're standing up and saying, I will fight back. ”

Leaders in politics are also supporting the breakthrough. Prime Minister Andy Burnham, who recently lost his father to Alzheimer's, commended the UK-backed program for providing families dealing with the terrible reality of the illness with state-of-the-art treatments.

1,200 people with mild to moderate Alzheimer's will be recruited for the experiment in 30 locations in the UK, including Southampton, Edinburgh, and London. By 2030, scientists intend to evaluate this initial class of medications. If it is effective, it will demonstrate that using the secure, well-known instruments we already have in our medicine cabinets may be the quickest way to unravel our greatest medical mysteries.

To register their information or find out more about the trial, patients or their families can go to the official AD-SMART Portal.

FAQs:

Q: What is the AD-SMART trial?

A: The AD-SMART trial is a multi-arm, multi-stage platform, a strategy that has proven extremely effective in cancer research.

Q: Which specific drugs are being tested first in the AD-SMART trial ?

A: The AD-SMART trial is testing Metformin (for diabetes) and Atomoxetine (for ADHD).

Q: Who can participate in the AD-SMART clinical trial?

A: 1,200 people with mild to moderate Alzheimer's will be recruited for the experiment in 30 locations in the UK

Q: Why are these specific medications being used in the AD-SMART trial?

A: Both medications are believed to target and reduce harmful brain inflammation.

Q: How can people sign up for the AD-SMART clinical trial?

A: To register their information or find out more about the trial, patients or their families can go to the official AD-SMART Portal.